-
★
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection
(Hinzugefügt: 24.01.2022 um 19:51 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34548407/
-
★
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
(Hinzugefügt: 30.04.2021 um 05:40 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00676-0/fulltext
-
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
(Hinzugefügt: 30.12.2022 um 15:16 Uhr)
https://www.gene.com/media/press-releases/14979/2022-12-21/fda-approves-genentechs-actemra-for-the-
-
Baricitinib versus tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: A prospective, investigational, real-world study
(Hinzugefügt: 18.11.2022 um 15:58 Uhr)
https://www.ijidonline.com/article/S1201-9712(22)00577-X/fulltext
-
Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
(Hinzugefügt: 30.10.2022 um 09:21 Uhr)
https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(22)00529-8/fulltext?dgcid=raven_jbs_aip_email
-
IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
(Hinzugefügt: 19.09.2022 um 12:54 Uhr)
https://www.frontiersin.org/articles/10.3389/fmed.2020.583897/full?twclid=25m5ow701hybo8v9dur5dvpp8a&utm_source=ad&utm_medium=tw&utm_campaign=ba_sci-ib_fmed
-
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection
(Hinzugefügt: 09.05.2022 um 08:52 Uhr)
https://pubmed.ncbi.nlm.nih.gov/35473844/
-
Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials
(Hinzugefügt: 09.05.2022 um 08:52 Uhr)
https://www.ejinme.com/article/S0953-6205(22)00140-6/fulltext
-
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
(Hinzugefügt: 29.03.2022 um 10:26 Uhr)
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00092-X/fulltext
-
Mortality Rates Among Hospitalized Patients With COVID-19 Infection Treated With Tocilizumab and Corticosteroids
(Hinzugefügt: 11.03.2022 um 11:20 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2789444
-
ROACTEMRA: Corona-Patienten dürfen mit Roche-Arzneimittel behandelt werden
(Hinzugefügt: 09.12.2021 um 16:45 Uhr)
https://www.20min.ch/story/corona-patienten-duerfen-mit-roche-arzneimittel-behandelt-werden-724875747135
-
EMA: Tocilizumab bei schwerem COVID-19 zugelassen
(Hinzugefügt: 09.12.2021 um 08:23 Uhr)
https://www.aerzteblatt.de/nachrichten/129863/EMA-Tocilizumab-bei-schwerem-COVID-19-zugelassen
-
Bei schweren Verläufen EMA lässt Arthritis-Medikament für Covid-19 zu
(Hinzugefügt: 07.12.2021 um 07:17 Uhr)
https://www.n-tv.de/wissen/EMA-laesst-Arthritis-Medikament-fuer-Covid-19-zu-article22980564.html
-
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection
(Hinzugefügt: 04.10.2021 um 09:12 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34548407/
-
Engpässe bei Notfallmedikament gegen Corona erwartet, WHO besorgt
(Hinzugefügt: 24.08.2021 um 16:23 Uhr)
https://www.aerzteblatt.de/nachrichten/126518/Engpaesse-bei-Notfallmedikament-gegen-Corona-erwartet-WHO-besorgt
-
WHO empfiehlt IL-6-Antagonisten bei COVID-19
(Hinzugefügt: 14.07.2021 um 09:59 Uhr)
https://www.aerzteblatt.de/nachrichten/125369/WHO-empfiehlt-IL-6-Antagonisten-bei-COVID-19
-
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
(Hinzugefügt: 14.07.2021 um 09:59 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2781880
-
Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19
(Hinzugefügt: 30.06.2021 um 15:24 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19
-
Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19 A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial
(Hinzugefügt: 27.05.2021 um 15:37 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2780021
-
Tocilizumab in COVID-19: some clarity amid controversy
(Hinzugefügt: 30.04.2021 um 05:41 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00712-1/fulltext
-
TOCILIZUMAB (ROACTEMRA): INTERLEUKIN-6-REZEPTORANTAGONIST GEGEN COVID-19
(Hinzugefügt: 19.03.2021 um 21:11 Uhr)
https://www.arznei-telegramm.de/html/2021_03/2103405_01.html
-
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
(Hinzugefügt: 05.03.2021 um 06:45 Uhr)
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00081-3/fulltext
-
COVID-19: Wann erzielt Tocilizumab die beste Wirkung?
(Hinzugefügt: 27.02.2021 um 07:12 Uhr)
https://www.aerzteblatt.de/nachrichten/121570/COVID-19-Wann-erzielt-Tocilizumab-die-beste-Wirkung
-
Tocilizumab reduces deaths in patients hospitalised with COVID-19
(Hinzugefügt: 12.02.2021 um 08:14 Uhr)
https://www.ox.ac.uk/news/2021-02-11-tocilizumab-reduces-deaths-patients-hospitalised-covid-19
-
Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows
(Hinzugefügt: 12.02.2021 um 08:13 Uhr)
https://www.bmj.com/content/bmj/372/bmj.n433.full.pdf
-
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
(Hinzugefügt: 21.01.2021 um 19:21 Uhr)
https://www.bmj.com/content/372/bmj.n84
-
Update on recruitment to convalescent plasma and tocilizumab treatment arms
(Hinzugefügt: 12.01.2021 um 07:37 Uhr)
https://www.recoverytrial.net/news/update-on-recruitment-to-convalescent-plasma-and-tocilizumab-treatment-arms-statement-from-the-recovery-trial-chief-investigators
-
REMAP-CAP-Studie: Tocilizumab und Sarilumab senken Sterberisiko bei schwerem COVID-19
(Hinzugefügt: 09.01.2021 um 10:26 Uhr)
https://www.aerzteblatt.de/nachrichten/119982/REMAP-CAP-Studie-Tocilizumab-und-Sarilumab-senken-Sterberisiko-bei-schwerem-COVID-19
-
Tocilizumab enttäuscht in weiterer Studie mit Covid-19-Patienten
(Hinzugefügt: 08.01.2021 um 09:54 Uhr)
https://www.pharmazeutische-zeitung.de/tocilizumab-enttaeuscht-in-weiterer-studie-mit-covid-19-patienten-121318/
-
Tocilizumab effective in treating sickest COVID-19 patients
(Hinzugefügt: 08.01.2021 um 09:52 Uhr)
https://www.recover-europe.eu/tocilizumab-effective-in-treating-sickest-covid-19-patients/
-
NHS patients to receive life-saving COVID-19 treatments that could cut hospital time by 10 days
(Hinzugefügt: 08.01.2021 um 09:52 Uhr)
https://www.gov.uk/government/news/nhs-patients-to-receive-life-saving-covid-19-treatments-that-could-cut-hospital-time-by-10-days
-
Roche, Sanofi arthritis drugs reduce death rates among sickest COVID-19 patients
(Hinzugefügt: 08.01.2021 um 09:48 Uhr)
https://www.reuters.com/article/us-health-coronavirus-treatments-idUSKBN29C27V